We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Aggressive Breast Cancer Identified with Fluorescent Technique

By LabMedica International staff writers
Posted on 21 Jul 2016
Ductal carcinoma in situ (DCIS) of the breast is the most common type of non-invasive breast cancer and in DCIS, epithelial cells proliferate within ducts, which are surrounded by a double layer of myoepithelial cells and basement membranes.

Although epidemiological studies propose aggressive and non-aggressive forms of ductal DCIS, they cannot be identified with conventional histopathology and because of this, to be safe, most patients undergo aggressive treatment.

Scientists at the University of Michigan Medical School (Ann Arbor, MI, USA) used a new method, called biomarker ratio imaging microscopy (BRIM), to evaluate the co-expression of biomarkers correlating and anti-correlating with breast cancer aggressiveness in a retrospective study of DCIS samples. More...
BRIM combines traditional microscope techniques that pathologists use to examine tissue with mathematical analysis. The technique compares levels of different biomarkers, which can be seen as different fluorescent colors in stained tissue under a microscope.

Fluorescence microscopy was performed using a TE2000-U inverted microscope (Nikon, Melville, NY, USA) and an Andor iXon camera (Andor Technology, Belfast, UK) with 100 W mercury lamp. The investigators looked at biopsy tissue samples from 23 patients with DCIS. They used fluorescent imaging, where the tissue samples are stained, to identify key biomarkers. Each biomarker was stained a different color. They then entered the images of the stained tissue samples into a computer that calculated the levels of different biomarkers in each pixel. In cancer, some biomarkers are present in high levels while others are less prolific. BRIM uses the ratio of these different levels to form an image of improved contrast.

The BRIM method found 22% of the samples had low ratios of cancer versus non-cancer biomarkers, suggesting those lesions were very slow-growing and non-aggressive. They note that an advantage of BRIM is that it uses several biomarkers rather than relying on only one. They decided which biomarkers to use after an extensive literature search. The authors concluded that the ability to stratify DCIS lesions and to identify potentially non-aggressive and aggressive lesions raises important issues in addressing overtreatment in breast cancer. BRIM is particularly attractive because it could be integrated into clinical pathology practices. Moreover, this approach may be useful in the cytologic study of aspirates in breast cancer and in peritoneal fluids in ovarian cancer. The study was published on June 1, 2016, in the journal Scientific Reports.

Related Links:
University of Michigan Medical School
Nikon
Andor Technology

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.